MXCT · Maxcyte, Inc.
$1.32
-0.07 (-5.04%)
At close · Aug 14
Market Cap
$136.23M
Shares
103.21M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$33.03M
-14.5%
FY2025
Net Income
-$44.63M
-8.7%
FY2025
Gross Margin
81.16%
-0.5pp
FY2025
Operating Margin
-157.14%
-24.6pp
FY2025
Diluted EPS
-$0.42
-7.7%
FY2025
Operating Cash Flow
-$34.41M
-24.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $31.05M | $33.03M | $38.63M | $41.29M | $44.26M | $33.89M | $26.17M | $21.62M | |
| $12.22M | $12.07M | $16.41M | $21.79M | $15.51M | $12.32M | $10.72M | $8.36M | |
| $6.45M | $6.22M | $7.1M | $4.74M | $5.1M | $3.65M | $2.77M | $2.5M | |
| $24.6M | $26.8M | $31.53M | $36.55M | $39.16M | $30.25M | $23.4M | $19.12M | |
| — | 81.16% | 81.62% | 88.51% | 88.48% | 89.24% | 89.43% | 88.44% | |
| $16.76M | $20.82M | $22.23M | $23.82M | $19.51M | $15.41M | $17.73M | $17.59M | |
| $14.23M | $18.92M | $26.66M | $26.98M | $18.65M | $13M | $8.33M | $7.85M | |
| $24.73M | $28.12M | $29.69M | $30.07M | $25.83M | $18.68M | $7.37M | $5.56M | |
| $65K | $53K | — | — | — | — | — | — | |
| $4.16M | $4.34M | $4.32M | $4.17M | $2.7M | $1.42M | $1.05M | $613.5K | |
| $66.39M | $78.7M | $82.72M | $84.85M | $66.52M | $48.44M | $34.46M | $31.54M | |
| -$41.79M | -$51.9M | -$51.2M | -$48.3M | -$27.36M | -$18.19M | -$11.06M | -$12.42M | |
| — | -157.14% | -132.54% | -116.98% | -61.82% | -53.66% | -42.25% | -57.44% | |
| -$37.63M | -$47.56M | -$46.88M | -$44.13M | -$24.66M | -$16.76M | -$10.01M | -$11.81M | |
| — | — | — | — | — | $5400 | $21.7K | $51.9K | |
| $6.16M | $7.27M | $10.14M | $10.38M | $3.92M | $150.8K | $65.9K | $206.1K | |
| $6.16M | $7.27M | $10.14M | $10.38M | $3.79M | -$893.6K | -$759.7K | -$475K | |
| -$35.64M | -$44.63M | -$41.06M | -$37.92M | — | — | — | — | |
| — | — | — | — | — | $0 | $0 | $0 | |
| -$35.64M | -$44.63M | -$41.06M | -$37.92M | -$23.57M | -$19.08M | -$11.82M | -$12.9M | |
| — | -135.14% | -106.29% | -91.85% | -53.25% | -56.3% | -45.15% | -59.64% | |
| USD/shares | — | -$0.42 | -$0.39 | -$0.37 | -$0.23 | -$0.21 | -$0.17 | -$0.23 |
| USD/shares | — | -$0.42 | -$0.39 | -$0.37 | -$0.23 | -$0.21 | -$0.17 | -$0.23 |
| shares | — | 106.43M | 104.85M | 103.27M | 101.7M | 90.62M | 69.46M | 56.4M |
| shares | — | 106.43M | 104.85M | 103.27M | 101.7M | 90.62M | 69.46M | 56.4M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.84×
EV/EBIT
—
Peer median 15.23×
P/E (TTM)
—
Peer median 31.70×
Peer medians compare against the 80 similar-size Medical Devices companies (of 148 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cell Engineering Technology Segment | $33,026,000 | $38,627,000 | $41,288,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $21,078,000 | $25,768,000 | $32,420,000 |
| Non Us | $11,948,000 | $12,859,000 | $8,868,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $18,691,000 | $21,089,000 | $18,600,000 | $27,730,000 | $20,786,800 | $14,850,200 | $12,917,800 |
| License | $12,369,000 | $16,412,000 | — | — | — | — | — |
| Assay And Other Service Revenue | $1,966,000 | — | — | — | — | — | — |
| Product And Service Other | — | $1,126,000 | $897,000 | $1,018,000 | $784,600 | $601,300 | $339,400 |